Looks like you’re on the UK site. Choose another location to see content specific to your location

Home Industry News Gilead Sciences receives provisional NICE backing for Sovaldi

Gilead Sciences receives provisional NICE backing for Sovaldi

15th August 2014

Gilead Sciences' Sovaldi has been provisionally recommended by the UK National Institute for Health and Care Excellence (NICE) for the treatment of chronic hepatitis C.

New draft guidance issued by the regulator has endorsed the drug for use in combination with peginterferon alfa and ribavirin, or ribavirin alone, among hepatitis C patients affected by certain genotypes of the disease.

Previously, NICE had chosen not to recommend the drug, but Gilead has since provided the organisation with additional information about the product's cost effectiveness, prompting a change of stance.

A new consultation has now been launched on the draft guidance, giving relevant stakeholders the opportunity to offer comment on the recommendations between now and September 5th 2014.

Professor Carole Longson, director of the NICE Centre for Health Technology Evaluation, said: "We are pleased to be able to provisionally recommend sofosbuvir as a clinically and cost-effective treatment for some people with chronic hepatitis C."

The once-daily oral nucleotide analogue polymerase inhibitor therapy was approved by the European Commission in January 2014 after proving its safety and efficacy in four phase III trials.ADNFCR-8000103-ID-801742333-ADNFCR

We currently have 9 jobs available in Pharmacy industry, find your perfect one now.

Stay informed

Receive the latest industry news, Tips
and straight to your inbox.